|
|
VCU Massey Cancer Center Support Grant
|
2P30CA016059-36
|
$2,164,167
|
$108,208
|
GINDER, GORDON
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
|
VCU Massey Cancer Center Support Grant
|
3P30CA016059-36S1
|
$124,341
|
$6,217
|
GINDER, GORDON
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
|
VCU Massey Cancer Center Support Grant
|
3P30CA016059-36S2
|
$19,990
|
$1,000
|
GINDER, GORDON
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
|
USC Norris Comprehensive Cancer Center (Core) Grant
|
3P30CA014089-42S1
|
$59,999
|
$600
|
Wayne, Alan
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
|
USC Norris Comprehensive Cancer Center (Core) Grant
|
5P30CA014089-42
|
$6,263,488
|
$62,635
|
Wayne, Alan
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
|
University of Colorado Cancer Center Support Grant
|
2P30CA046934-29
|
$3,880,607
|
$38,806
|
THEODORESCU, DAN
|
UNIVERSITY OF COLORADO DENVER
|
|
|
University of Colorado Cancer Center Support Grant
|
3P30CA046934-29S1
|
$3,780
|
$38
|
THEODORESCU, DAN
|
UNIVERSITY OF COLORADO DENVER
|
|
|
University of Colorado Cancer Center Support Grant
|
3P30CA046934-29S2
|
$104,106
|
$1,041
|
THEODORESCU, DAN
|
UNIVERSITY OF COLORADO DENVER
|
|
|
Understanding resistance in the HER2-HER3 tumor drive
|
5R01CA122216-10
|
$298,554
|
$74,639
|
MOASSER, MARK
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
|
U.T. M. D. Anderson Cancer Center SPORE in Ovarian Cancer
|
1P50CA217685-01
|
$1,732,856
|
$346,571
|
BAST, ROBERT
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
|
Tumor-targeted Polymersomes to image and Treat Ovarian Cancer
|
5R01CA175480-05
|
$327,536
|
$163,768
|
CHENG, ZHILIANG
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Tumor-targeted nanoparticle-based delivery system for imaging and treatment of cancer
|
1R01CA209818-01A1
|
$470,010
|
$117,503
|
MINKO, TAMARA
|
RUTGERS, THE STATE UNIV OF N.J.
|
|
|
Tumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer: a tripartite USA/Northern Ireland/Republic of Ireland consortium
|
5R01CA198096-03
|
$429,377
|
$141,694
|
STRAUBINGER, ROBERT
|
STATE UNIVERSITY OF NEW YORK AT BUFFALO
|
|
|
Total Synthesis and Biosynthesis of Bioactive Substances
|
5R01CA070375-21
|
$256,101
|
$128,051
|
WILLIAMS, ROBERT
|
COLORADO STATE UNIVERSITY
|
|
|
Therapeutic Targeting Agents for Ovarian Cancer
|
5R01CA115483-13
|
$345,660
|
$345,660
|
LAM, KIT
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
|
|
Theranostic nanoparticles for the treatment of RAI refractory thyroid cancer
|
5R01CA178007-05
|
$351,713
|
$175,857
|
JIN, MOONSOO
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
|
The Role of USP22 in Prostate Cancer Development and Progression
|
5F99CA212225-02
|
$44,044
|
$13,213
|
MCCANN, JENNIFER
|
THOMAS JEFFERSON UNIVERSITY
|
|
|
The role of ENF loss, TLR4 and spinal plasticity in paclitaxel CIPN
|
5R01CA200263-02
|
$479,883
|
$479,883
|
DOUGHERTY, PATRICK
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
|
The mechanism of DNA damage and chromothripsis from chromosome segregation errors
|
5K08CA208008-02
|
$177,120
|
$177,120
|
SPEKTOR, ALEXANDER
|
DANA-FARBER CANCER INST
|
|
|
The Evaluation of Novel Therapeutics for Genitourinary Malignancies
|
ZIA SC 010098
|
$625,665
|
$31,283
|
Dahut, William
|
CCR (NCI)
|
|
|
Targeting Stromal Collagen in Pancreatic Cancer
|
5R01CA169281-05
|
$386,727
|
$193,364
|
HAN, HAIYONG
|
TRANSLATIONAL GENOMICS RESEARCH INST
|
|
|
Targeting BET proteins in Triple Negative Breast Cancer
|
5R01CA206505-02
|
$366,913
|
$183,457
|
KERI, RUTH
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies
|
2R44CA162629-02A1
|
$1,154,726
|
$288,682
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
|
Targeted therapeutics for ovarian cancer and its microenvironment - treatment and theoretical modeling
|
1U01CA213759-01
|
$515,198
|
$170,015
|
LOPEZ-BERESTEIN, GABRIEL
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
|
Targeted Nanotherapy for Pancreatic Cancer
|
5R01CA210192-02
|
$347,700
|
$173,850
|
CHAUHAN, SUBHASH
|
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
|
|
|
Targeted Combination Therapy for Breast Cancer
|
5R01CA174305-04
|
$313,323
|
$313,323
|
LI, SONG
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
|
Stimuli-responsive crosslinked theranostics against advanced prostate cancer
|
5R01CA199668-03
|
$359,138
|
$118,516
|
LI, YUANPEI
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
|
|
Stanford Cancer Institute
|
5P30CA124435-10
|
$3,338,488
|
$33,385
|
MITCHELL, BEVERLY
|
STANFORD UNIVERSITY
|
|
|
SPORE: Developing New Rationale, Personalized Medicine for Lung Cancer
|
5P50CA070907-19
|
$2,299,998
|
$115,000
|
MINNA, JOHN
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
|
SPORE: Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer
|
5P50CA168504-05
|
$2,051,965
|
$61,559
|
WINER, ERIC
|
DANA-FARBER CANCER INST
|
|
|
SPORE in Breast Cancer
|
5P50CA098131-16
|
$2,300,000
|
$575,000
|
PIETENPOL, JENNIFER
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
|
Single Cell In Vivo Imaging Technology to Analyze Taxane Nano Formulations in Breast Cancer
|
5K99CA207744-02
|
$179,280
|
$179,280
|
MILLER, MILES
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
|
Role of Oncogenic Kinase Pim-1 in Prostate Cancer
|
5R01CA123484-10
|
$284,744
|
$71,186
|
ABDULKADIR, SARKI
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
|
Regulators of NaV1.7 Channels: Novel Anti-Allodynic Drug Candidates
|
1R41CA210857-01A1
|
$299,999
|
$299,999
|
KHANNA, RAJESH
|
REGULONIX, LLC
|
|
|
Regional Oncology Research Center
|
2P30CA006973-54
|
$7,060,038
|
$70,600
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
|
Regional Oncology Research Center
|
3P30CA006973-54S1
|
$125,000
|
$1,250
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
|
Regional Oncology Research Center
|
3P30CA006973-54S2
|
$60,000
|
$600
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
|
Regional Oncology Research Center
|
3P30CA006973-54S3
|
$25,000
|
$250
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
|
Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy
|
5U01CA142565-09
|
$461,999
|
$231,000
|
ABRAMSON, RICHARD
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
|
PSMA Targeted Docetaxel Loaded Magnetic Nanoparticles for Prostate Cancer Therapy
|
5K22CA174841-03
|
$160,992
|
$160,992
|
YALLAPU, MURALI
|
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
|
|
|
Program Project in Models of Breast Cancer
|
5P01CA094060-14
|
$2,620,541
|
$131,027
|
NORTON, LARRY
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
|
Precision nanotherapeutics for cancer treatment
|
1R01CA207584-01A1
|
$412,532
|
$412,532
|
CHENG, JIANJUN
|
UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN
|
|
|
Pharmacogenomics of Microtubule Targeting Agents
|
5R01CA192156-03
|
$735,702
|
$242,782
|
KROETZ, DEANNA
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
|
Perfluorocarbon Nanodroplets for the Detection and Treatment of Nodal Metastases
|
1F30CA216939-01A1
|
$49,044
|
$14,713
|
YARMOSKA, STEVEN
|
EMORY UNIVERSITY
|
|
|
Pathophysiologic Consequences of Neurotrophin Activation of Trk in Neuroblastoma
|
ZIA BC 010789
|
$358,450
|
$35,845
|
Thiele, Carol
|
CCR (NCI)
|
|
|
Pancreatic Ductal Adenocarcinoma is a disease of constitutive autophagy
|
5R01CA181450-04
|
$319,550
|
$159,775
|
ZEH, HERBERT
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
|
Novel Bone-Targeting Combination Therapy for Osteosarcoma Phase II
|
2R44CA203166-02
|
$1,138,475
|
$1,138,475
|
ZINNEN, SHAWN
|
MBC PHARMA, INC.
|
|
|
NOS1AP as a novel target for treating pathological pain
|
5R01CA200417-02
|
$281,910
|
$93,030
|
HOHMANN, ANDREA
|
INDIANA UNIVERSITY BLOOMINGTON
|
|
|
New therapeutic opportunities from mining polypharmacology mechanisms of ceritinib in ALK-negative non-small cell lung cancer
|
5F99CA212456-02
|
$34,324
|
$17,162
|
KUENZI, BRENT
|
UNIVERSITY OF SOUTH FLORIDA
|
|
|
Neuropilin-2 Axis in Docetaxel Resistance and Prostate Cancer Bone Metastasis
|
5R01CA182435-03
|
$344,269
|
$344,269
|
DATTA, KAUSTUBH
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
Total relevant funding to Taxol for this search: $21,807,981
|
